Latest News & Updates

Breaking News

  • 19 hours ago

  • Simantini Singh Deo

Replimune Group Wins FDA Advisory Committee Backing For RP1 Melanoma Therapy Ahead Of August 2 Decision
Breaking News
Abivax Aligns with FDA on NDA Strategy For Obefazimod, Remains On Track For 2026 Submission

Simantini Singh Deo

Other trending news you may like to read

Replimune Group Wins FDA Advisory Committee Backing For RP1 Melanoma Therapy Ahead Of August 2 Decision

Replimune Group wins a 10-3 FDA advisory committee vote backing its RP1 melanoma therapy, ahead of the agency's August 2, 2026 decision date.

Simantini Singh Deo

Pharma Now

Abivax Aligns with FDA on NDA Strategy For Obefazimod, Remains On Track For 2026 Submission

Abivax aligns with the FDA on its NDA submission strategy for obefazimod, remaining on track for a 2026 filing to treat ulcerative colitis.

Simantini Singh Deo

Pharma Now

Keros Therapeutics Earns $20 Million Milestone Payment From Takeda After First Patient Dosed In Phase 3 ELRiSE MDS Trial

Keros Therapeutics earns a $20 million milestone payment from Takeda after the first patient is dosed in the Phase 3 ELRiSE MDS trial for elritercept.

Simantini Singh Deo

Pharma Now

Annexon Secures Up to $200 Million Credit Facility From Oxford Finance To Support Commercial Growth

Annexon secures a non-dilutive credit facility worth up to $200 million from Oxford Finance to support commercial growth of its lead drug candidates.

Simantini Singh Deo

Pharma Now